ReviewFrontiers in pharmacology2021
New Insights Into the Effects of Individual Chinese Herbal Medicines on Chronic Kidney Disease.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Therapeutic Effect of Natural Products and Dietary Supplements on Aflatoxin-Induced Nephropathy.International journal of molecular sciences · 2024Pooled it
- TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis.Frontiers in pharmacology · 2022Pooled it
- Exploring Chinese Herbal Medicines for Acute Kidney Injury: Pharmacological Mechanisms and Clinical Potential.Drug design, development and therapy · 2026Review
- ST32da, a NovelCells · 2025Article
- Pharmacological Mechanism of Chinese Medicine in Systemic Lupus Erythematosus: A Narrative Review.Chinese journal of integrative medicine · 2025Review
- Mechanistic Insights Into Celastrol's Anti-Pyroptosis Effects in Osteoarthritis via SIRT2 Upregulation.Mediators of inflammation · 2025Article
- Clinical efficacy and safety of tripterygium wilfordii glycosides in the treatment of idiopathic membranous nephropathy: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Article
- Unveiling the therapeutic potential of berberine: its therapeutic role and molecular mechanisms in kidney diseases.Frontiers in pharmacology · 2025Review
- Article
- Puerarin-A Promising Flavonoid: Biosynthesis, Extraction Methods, Analytical Techniques, and Biological Effects.International journal of molecular sciences · 2024Review
- A new perspective on proteinuria and drug therapy for diabetic kidney disease.Frontiers in pharmacology · 2024Review
- Advances in the pharmacological mechanisms of berberine in the treatment of fibrosis.Frontiers in pharmacology · 2024Review
- Network-Pharmacology-Based Study on Active Phytochemicals and Molecular Mechanism of Cnidii Fructus in Treating Colorectal Cancer.Combinatorial chemistry & high throughput screening · 2024Article
- Study of Active Phytochemicals and Mechanisms of Cnidii Fructus in Treating Osteoporosis Based on HPLC-Q-TOF-MS/MS and Network Pharmacology.Combinatorial chemistry & high throughput screening · 2024Article
- Salvianolic acid B attenuates tubulointerstitial fibrosis by inhibiting EZH2 to regulate the PTEN/Akt pathway.Pharmaceutical biology · 2023Article
- Baicalin inhibits the replication of the hepatitis B virus by targeting TRIM25.Journal of traditional and complementary medicine · 2023Article
- Article
- BaoShenTongLuo formula protects against podocyte injury by regulating AMPK-mediated mitochondrial biogenesis in diabetic kidney disease.Chinese medicine · 2023Article
- Network Pharmacology Analysis and Machine-Learning Models Confirmed the Ability of YiShen HuoXue Decoction to Alleviate Renal Fibrosis by Inhibiting Pyroptosis.Drug design, development and therapy · 2023Article
- Natural products for kidney disease treatment: Focus on targeting mitochondrial dysfunction.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical and experimental study into the effects of Chinese herbal medicines on chronic kidney disease has evolved over the past 40 years with new insight into their mechanism and evidence of their clinical effects. Among the many traditional Chinese herbs examined in chronic renal disease, five were found to have evidence of sufficient clinical efficacy, high frequency of use, and well-studied mechanism. They are:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.